

pLGG disease burden and healthcare utilization: linked claims and EHR data study

Tabitha Cooney,^{1,2} Sandie Yu,² Shailaja Daral,³ Blake Krebs,³ Riddhi Markan,³ Michelle A Field,³ Mark Kieran,² Sandya Govinda Raju,² Susan Zelt²

2023 ASPHO Conference: Poster 258

¹Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; ²Day One Biopharmaceuticals, Brisbane, CA; ³Optum Lifesciences Inc. Eden Prairie, MN

Background

- Pediatric low-grade glioma (pLGG), the most common brain tumor in children, is an indolent disease with insidious symptoms that progress over months to years¹⁻⁴
- Despite excellent long-term survival, pLGGs cause significant tumor- and treatment-associated morbidities and significant late effects that persist throughout life⁴⁻⁶

Objective

- We conducted a retrospective study of linked claims and electronic health records (EHRs) to gain insights into the disease burden and healthcare utilization of patients with pLGG

Methods

- We performed a retrospective study using the Optum[®] de-identified Market Clarity Dataset linked claims (commercial, Medicare advantage and Managed Medicaid beneficiaries) and EHRs of cases ≤18 years of age, with an ICD-10 code for brain neoplasm and ≥1 physician notes between January 01, 2017 and June 30, 2018 (**Figure 1**)
- The index date was first claim or EHR with an ICD-10 code for brain neoplasm
- Natural language processing was used to identify pLGG-relevant data from physician notes
- The observation period included 3 months prior to index date (pre-index) and 6-month segments from index date for 36 months (post-index)
- Cases had either continuous insurance coverage or continuous EHR activity in this period

Results

- Of 2841 patients assessed for eligibility, a total of 154 patients with pLGG were identified (**Figure 2**)
- Median age was 11 years, 49% were female and 75% were non-Hispanic white (**Table 1**)
- Study results are reported with ranges over a three-year follow-up period (**Figures 3–10**)

Figure 1. Study design




Figure 2. Consort diagram




Table 1. Baseline demographics and insurance coverage

	n=154
Age in years, median (range)	11 (2–18)
Male, n (%)	78 (51)
Female, n (%)	76 (49)
Race, n (%)	
Caucasian	116 (75)
Hispanic	20 (13)
African American	7 (5)
Asian	1 (<1)
Other/unknown	10 (6)
Insurance, n (%)	
Commercial	86 (56)
Medicaid	68 (44)

Figure 3. Top 25 reasons for healthcare utilization in the overall study period (n=154)




Figure 4. Select reasons for healthcare utilization over time in 6-month intervals*



*n for each of the time periods indicates the number of patients in the study cohort that had ≥1 EHR of symptoms and signs of pLGG for that time period

Figure 5. Select coexisting conditions in the overall study period (n=154)





Figure 6. Select coexisting conditions over time in 6-month intervals*



*n for each of the time periods indicates the number of patients in the study cohort that had ≥1 claims or EHR for that time period

Figure 7. Healthcare providers consulted in the overall study period (n=154)





Figure 8. Healthcare providers consulted over time in 6-month intervals*



PMR, physical medicine and rehabilitation
*n for each of the time periods indicates the number of patients in the study cohort that had ≥1 claims or EHR for that time period

Figure 9. Places of healthcare services in the overall study period (n=154)





Figure 10. Places of healthcare service in 6-month intervals*



*n for each of the time periods indicates the number of patients in the study cohort that had ≥1 claims or EHR for that time period
*Inpatient stays: 3-month pre-index (n=36); 36-month post-index (n=74); emergency rooms stays: 3-month pre-index (n=42); 36-month post-index (n=84)

Conclusions

- Despite the low-grade classification, patients with pLGG experience significant symptomatology and have complex healthcare needs that require high utilization of healthcare services, that persist over years
- Further studies using integrated data sources are warranted to help us better understand the disease burden of pLGG

References

- Goldman R, et al. *CMAJ*. 2017;189(12):E459–E463.
- Sievert A and Fisher M. *J Child Neurol*. 2009;24(11):1397–1408.
- Bandopadhyay P, et al. *Pediatr Blood Cancer*. 2014;61(7):1173–1179.
- Ryall S, et al. *Acta Neuropathol Commun*. 2020;8(1):30.
- de Blank P, et al. *Curr Opin Pediatr*. 2019;31(1):21–27.
- Traunwieser T, et al. *Neurooncol Adv*. 2020;2(1):vdaa094.

Acknowledgments

This study was supported by Day One Biopharmaceuticals. For further information, contact Susan Zelt (susan.zelt@dayonebio.com). Tabitha Cooney was affiliated with Dana-Farber/Boston Children's when the study was performed and is currently an employee of Day One Biopharmaceuticals.